Stereotactic Body Radiation Therapy for Breast Cancer
Breast Cancer
About this trial
This is an interventional treatment trial for Breast Cancer
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed diagnosis of invasive breast carcinoma of non-lobular histology.
Unifocal tumour Previously assessed by a breast surgeon and medical oncologist, with no surgery being recommended at time of enrollment.
Primary breast and axillary surgery not recommended/performed due to any of the following:
- distant metastatic disease
- unresectable T4 disease and/or
- medically inoperable and/or
- patient declined breast surgery Stages T1-T4, N1-N2, M0-M1 disease Ability to attend radiation planning and therapy, able to attend for follow-up care Able to provide written informed consent.
Exclusion Criteria:
Received chemotherapy within 3 weeks prior to breast SBRT. (Concurrent endocrine therapy is permitted) Multifocal or multicentric tumours. Ipsilateral supraclavicular or infraclavicular nodal disease >= 1cm size that is at the level of or superior to the brachial plexus Unable to meet the brachial plexus dose constraints despite compromising coverage of target volumes - as per the discretion of the treating physician Treatment target volume estimated to occupy > 50% of the ipsilateral whole breast volume.
Locally recurrent breast cancer, with previous radiotherapy to the breast, or previous lumpectomy or mastectomy. Ipsilateral breast implant. Serious non-malignant disease that precludes definitive surgical or radiation treatment (e.g.
scleroderma, systemic lupus erythematosus, cardiovascular/pulmonary/renal disease).
Women who are pregnant or lactating. Psychiatric or addictive disorders that preclude obtaining informed consent or adherence to protocol
Sites / Locations
- Sunnybrook Odette Cancer CentreRecruiting
Arms of the Study
Arm 1
Experimental
SBRT to the Primary Breast Tumour
SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.